Holzer & Holzer, LLC announced an investigation into whether Immix Biopharma, Inc. complied with federal securities laws. The investigation follows Immix's July 20, 2026 disclosure that it terminated its Chief Medical Officer after news reports revealed the CMO had been using a false identity and was a recently captured fugitive. The company's stock price dropped following the announcement. Investors who purchased Immix stock and suffered a loss are encouraged to contact the law firm.
Immix Biopharma IncInvestigation into securities law compliance and CMO termination for using false identity and being a fugitive